Australia, Aug. 18 -- CRISPR Therapeutics AG, owns the trademark (2635972) for 'CTX611' till March 16, 2036.
Status: registered:
Registered/protected
Classes: 5 [Cells for medical or clinical use in the field of gene therapy for the treatment of cardiovascular diseases and thromboembolic diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy], 42 [Gene editing, namely, medical and scientific research ...